$CL

Colgate-Palmolive exploring $1B divestment of select brands, Reuters reports

Colgate-Palmolive (NYSE:CL) is exploring the sale of brands like Softsoap, Irish Spring, and Speed Stick, potentially fetching over $1B. The company is working with Goldman Sachs to streamline its portfolio amid macroeconomic challenges, focusing on core categories like oral care. CL's market cap is approximately $70B, with shares up about 4% over the past year.

Original reporting
Published Sep 11, 2026, 3:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 3:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$CL
Neutral
medium confidence
Mentioned
$CL
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CLNeutralMed
01

Why it matters

Exploratory sale of non‑core brands may improve balance‑sheet strength but could reduce revenue diversification.

02

Market read

The news introduces a material strategic shift for a large consumer‑goods company, offering a watchable catalyst for traders.

03

What to watch

Potential buyer interest and valuation multiples are uncertain; execution risk remains high.

Relevance 7/10Novelty 8/10Timing: current

Background

Colgate-Palmolive has been focusing on core oral‑care and pet‑nutrition businesses amid macro headwinds.

Company-level read

Ticker impact

$CLNeutralMedium confidence
Context

Colgate-Palmolive is exploring the sale of several personal care brands for over $1 billion.

Expected impact

modest downside risk as investors assess the impact on earnings

Evidence & confidence

The $1B size is material for a $70B market cap, but the transaction is only exploratory.

Market effects

May prompt other consumer‑goods peers to consider portfolio trims.

Limited to North American consumer staples investors.

Modest, as the move reflects broader CPG sector consolidation trends.

Counterpoint

The divestiture could be a catalyst for upside if proceeds fund high‑growth oral‑care initiatives.

Key entities

  • Goldman Sachs

    Advising Colgate on the potential divestiture.

Related articles

$CLMedAI 8/10

Palmolive seeks to divest some personal care brands, sources say

Colgate-Palmolive is considering selling some personal care brands, including Softsoap, Irish Spring, and Speed Stick, potentially fetching over $1 billion. The company is working with Goldman Sachs on the process. Colgate's stock is up 11% year-to-date, with net sales rising 4.9% in the latest quarter, though North American organic sales fell 3%. The personal care unit accounts for 17% of net sales.

$PGMed

Weather Dividend Stocks That Keep Writing Bigger Checks

Procter & Gamble (PG) raised its dividend for 70 consecutive years, with fiscal 2026 free cash flow of $15.835B. Coca-Cola (KO) reported 5% unit case volume growth, its strongest in 17 years. Colgate-Palmolive (CL) saw 16.12% YTD stock growth and raised its dividend. All three companies demonstrated recession-resilient cash flows and dividend increases.

$PGMedAI 8/10

2 Dividend Kings, 1 Clear Winner: P&G vs. Colgate

Procter & Gamble (PG) and Colgate-Palmolive (CL) recently paid dividends. PG offers a higher yield (2.93%) and better coverage, while CL has stronger recent price performance. PG plans to return $15B to shareholders in fiscal 2027, including $10B in dividends. CL trades at a higher P/E (35x) with a smaller yield (2.33%).

$CLHigh

Colgate-Palmolive India Share Price Target at Rs 2,500: Motilal Oswal

Motilal Oswal reaffirmed a BUY rating for Colgate-Palmolive India, setting a price target of Rs 2,500, a 27% upside from the current price of Rs 1,965. The brokerage values the company at 40 times its estimated March 2027 earnings, citing strong growth pillars, premiumisation, and high margins. Colgate's strategy focuses on consumption creation and scientific premiumisation, with a 52-week range of Rs 1,782–2,505.